EIM
NKTR icon

Essex Investment Management’s Nektar Therapeutics NKTR Stock Holding History

Essex Investment Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-204
Closed -$101K – 499
2018
Q4 		$101K Buy
+204
New +$123K 0.02% 373

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Essex Investment Management's NKTR Position: Q1 2019 in Review

Essex Investment Management sold out of Nektar Therapeutics (NKTR) in Q1 2019, closing a stake of 204 shares — an estimated $101K sold.

Essex Investment Management first reported a position in NKTR in Q4 2018 and held it in 1 quarter. The position peaked at $101K in Q4 2018. 350 funds tracked by Wall St. Rank hold NKTR as of Q1 2019.

  • Essex Investment Management reported no remaining Nektar Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Essex Investment Management sold 204 Nektar Therapeutics shares in Q1 2019, an estimated $101K.
  • Essex Investment Management first reported a position in Nektar Therapeutics in Q4 2018 and held it in 1 quarter.
  • Essex Investment Management's Nektar Therapeutics position peaked at $101K in Q4 2018.
  • 350 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2019.

Based on Essex Investment Management's 13F filing for Q1 2019, filed 15 May 2019.